JP2005516904A - 緊急避妊のための薬学的組成物およびその用量処方 - Google Patents
緊急避妊のための薬学的組成物およびその用量処方 Download PDFInfo
- Publication number
- JP2005516904A JP2005516904A JP2003546899A JP2003546899A JP2005516904A JP 2005516904 A JP2005516904 A JP 2005516904A JP 2003546899 A JP2003546899 A JP 2003546899A JP 2003546899 A JP2003546899 A JP 2003546899A JP 2005516904 A JP2005516904 A JP 2005516904A
- Authority
- JP
- Japan
- Prior art keywords
- levonorgestrel
- active ingredient
- formulation
- dose
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 238000009472 formulation Methods 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims abstract description 43
- 229960004400 levonorgestrel Drugs 0.000 claims abstract description 43
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 230000001568 sexual effect Effects 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 5
- 239000003381 stabilizer Substances 0.000 claims abstract 5
- 239000000796 flavoring agent Substances 0.000 claims abstract 4
- 230000000996 additive effect Effects 0.000 claims abstract 2
- 235000019634 flavors Nutrition 0.000 claims abstract 2
- 239000003205 fragrance Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000005454 flavour additive Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 abstract description 18
- 230000002254 contraceptive effect Effects 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000000843 powder Substances 0.000 description 8
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 7
- 229960001021 lactose monohydrate Drugs 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 6
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 5
- 229960002568 ethinylestradiol Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229940038565 levonorgestrel 1.5 mg Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002513 anti-ovulatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940124558 contraceptive agent Drugs 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000019100 sperm motility Effects 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000031271 Unwanted pregnancy Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940030877 levonorgestrel 0.75 mg Drugs 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105173A HU227198B1 (en) | 2001-11-27 | 2001-11-27 | Pharmaceutical composition for emergency contraception containing levonorgestrel |
| PCT/HU2002/000129 WO2003045397A1 (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516904A true JP2005516904A (ja) | 2005-06-09 |
| JP2005516904A5 JP2005516904A5 (enExample) | 2006-01-05 |
Family
ID=89998939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546899A Withdrawn JP2005516904A (ja) | 2001-11-27 | 2002-11-26 | 緊急避妊のための薬学的組成物およびその用量処方 |
Country Status (33)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513514A (ja) * | 2006-12-20 | 2010-04-30 | デュラメド ファーマシューティカルズ インコーポレーティッド | プロゲスチンを含む口腔内崩壊性固体剤形ならびにその製造方法および使用方法 |
| JP2012530733A (ja) * | 2009-06-23 | 2012-12-06 | バイエル ファーマ アクチエンゲゼルシャフト | 緊急避妊のための医薬組成物及び処置方法 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090170823A1 (en) * | 2007-12-20 | 2009-07-02 | Duramed Pharmaceuticals, Inc. | Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception |
| US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| EP2365811A1 (en) * | 2008-12-12 | 2011-09-21 | Laboratoire HRA Pharma | A method for contraception |
| WO2010119029A1 (en) | 2009-04-14 | 2010-10-21 | Laboratoire Hra-Pharma | Method for on-demand contraception |
| CN101732324B (zh) * | 2009-12-31 | 2011-12-07 | 广州朗圣药业有限公司 | 一种含有左炔诺孕酮的紧急避孕药物组合物及其制备方法 |
| RS54880B1 (sr) | 2011-06-01 | 2016-10-31 | Estetra Sprl | Postupak proizvodnje intermedijarnih proizvoda estetrola |
| ME02585B (me) | 2011-06-01 | 2017-06-20 | Estetra Sprl | Postupak proizvodnje intermedijara estetrola |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| CA2843951C (en) * | 2011-08-11 | 2019-08-06 | Wout WOUTERS | Use of estetrol as emergency contraceptive |
| SG11201503275RA (en) | 2012-11-22 | 2015-06-29 | Bayer Pharma AG | Use and application regimen of a pharmaceutical composition containing levonorgestrel and a cox inhibitor for on-demand contraception |
| CN105451737B (zh) | 2013-05-23 | 2018-04-10 | 拜耳医药股份有限公司 | 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法 |
| CN103877058A (zh) * | 2014-03-26 | 2014-06-25 | 邵娜 | 一种左炔诺孕酮片及其制备工艺 |
| EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
| MA44206B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
| CU24523B1 (es) | 2015-06-18 | 2021-06-08 | Estetra Sprl | Unidad de dosificación orodispersable que contiene un componente estetrol |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| EP3781171B1 (en) | 2018-04-19 | 2022-02-09 | Estetra SRL | Compounds and their uses for alleviating menopause-associated symptoms |
| CN110917154A (zh) * | 2019-12-12 | 2020-03-27 | 上海信谊天平药业有限公司 | 一种左炔诺孕酮片的制备方法 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022026901A2 (en) * | 2020-07-30 | 2022-02-03 | Acer Therapeutics Inc. | Nk antagonists for contraception |
| CN119523923A (zh) * | 2024-11-21 | 2025-02-28 | 华中药业股份有限公司 | 一种左炔诺孕酮片及其制备方法 |
-
2001
- 2001-11-27 HU HU0105173A patent/HU227198B1/hu unknown
-
2002
- 2002-11-26 DE DE60203929T patent/DE60203929T2/de not_active Expired - Lifetime
- 2002-11-26 EA EA200400731A patent/EA006545B1/ru unknown
- 2002-11-26 UA UA20040504015A patent/UA79942C2/uk unknown
- 2002-11-26 AT AT02783334T patent/ATE293978T1/de active
- 2002-11-26 EP EP02783334A patent/EP1448207B1/en not_active Expired - Lifetime
- 2002-11-26 BR BR0210595-0A patent/BR0210595A/pt not_active Application Discontinuation
- 2002-11-26 GE GE5567A patent/GEP20063882B/en unknown
- 2002-11-26 WO PCT/HU2002/000129 patent/WO2003045397A1/en not_active Ceased
- 2002-11-26 OA OA1200400148A patent/OA12730A/fr unknown
- 2002-11-26 KR KR1020047002069A patent/KR100908161B1/ko not_active Expired - Lifetime
- 2002-11-26 IL IL15939402A patent/IL159394A0/xx unknown
- 2002-11-26 ES ES02783334T patent/ES2239727T3/es not_active Expired - Lifetime
- 2002-11-26 RS YUP-42/04A patent/RS50768B/sr unknown
- 2002-11-26 JP JP2003546899A patent/JP2005516904A/ja not_active Withdrawn
- 2002-11-26 CN CNA028137523A patent/CN1551774A/zh active Pending
- 2002-11-26 SI SI200230132T patent/SI1448207T1/xx unknown
- 2002-11-26 PT PT02783334T patent/PT1448207E/pt unknown
- 2002-11-26 HR HR20040584 patent/HRP20040584B1/xx not_active IP Right Cessation
- 2002-11-26 AU AU2002347401A patent/AU2002347401A1/en not_active Abandoned
- 2002-11-26 CA CA2450359A patent/CA2450359C/en not_active Expired - Lifetime
- 2002-11-26 NZ NZ530056A patent/NZ530056A/en not_active IP Right Cessation
- 2002-11-26 PL PL369520A patent/PL206010B1/pl unknown
- 2002-11-26 AP APAP/P/2004/003046A patent/AP1849A/en active
- 2002-11-26 MX MXPA04005104A patent/MXPA04005104A/es active IP Right Grant
- 2002-11-26 DK DK02783334T patent/DK1448207T3/da active
-
2003
- 2003-12-05 IS IS7065A patent/IS2691B/is unknown
-
2004
- 2004-03-26 TN TNP2004000048A patent/TNSN04048A1/en unknown
- 2004-04-20 NO NO20041607A patent/NO333984B1/no not_active IP Right Cessation
- 2004-04-21 MA MA27643A patent/MA27076A1/fr unknown
- 2004-05-26 ZA ZA2004/04114A patent/ZA200404114B/en unknown
- 2004-06-25 EC EC2004005171A patent/ECSP045171A/es unknown
- 2004-10-05 US US10/495,923 patent/US20050288264A2/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513514A (ja) * | 2006-12-20 | 2010-04-30 | デュラメド ファーマシューティカルズ インコーポレーティッド | プロゲスチンを含む口腔内崩壊性固体剤形ならびにその製造方法および使用方法 |
| JP2012530733A (ja) * | 2009-06-23 | 2012-12-06 | バイエル ファーマ アクチエンゲゼルシャフト | 緊急避妊のための医薬組成物及び処置方法 |
| JP2015163646A (ja) * | 2009-06-23 | 2015-09-10 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 緊急避妊のための医薬組成物及び処置方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100908161B1 (ko) | 응급피임용 투약방법 및 약제학적 조성물 | |
| US8507465B2 (en) | Antiemetic-oral contraceptive combination | |
| JP6012048B2 (ja) | アロマターゼ阻害剤およびゲスターゲンを放出する、子宮内膜症を処置するための非経口用剤形 | |
| CN102458386B (zh) | 用于紧急避孕的药物组合物 | |
| RU2542779C2 (ru) | Способ контрацепции, используемый по мере необходимости | |
| Erkkola et al. | Role of progestins in contraception | |
| MD3310345T2 (ro) | Comprimată orodispersabilă ce conține estetrol | |
| KR20000048981A (ko) | 에스트로겐 화합물 및 프로게스테론 화합물로 이루어진 호르몬 조성물 | |
| JP2001523639A (ja) | プロゲストゲン−抗プロゲストゲンレジメン | |
| WO2010007629A1 (en) | A kit comprising anti-emetic and oral contraceptive | |
| RU2394579C2 (ru) | Применение комбинации из этинилэстрадиола и ацетата хлормадинона для приготовления лекарственного средства | |
| CN117715644A (zh) | 纯孕激素口服避孕 | |
| HK40108056A (en) | Progestogen-only oral contraception | |
| KR20010110807A (ko) | 조합 치료에서의 항프로게스타겐의 용도 | |
| HK1070275A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| JP2007197459A (ja) | 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬 | |
| HK1146391A (en) | Use of gestagens in combination with (6s)-5-methyltetrahydrofolate for the therapy of endometriosis with simultaneous reduction of therapy side effects and the reduction of the risk of congenital malformations in case of pregnancy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050706 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050706 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20060509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060509 |